News
SoundHound Breaks Critical Resistance: How High Can It Get Now?
SoundHound’s (NASDAQ: SOUN) share price advanced by more than 10% on September 23rd to set a fresh long-term high and potentially break the market out of its trading range. The implication of
AstraZeneca Aktie: Licht und Schatten bei Studienergebnissen
Der britische Pharmakonzern präsentierte diese Woche gemischte Nachrichten aus seiner Medikamentenentwicklung. Während eine Phase-III-Studie…
Der Beitrag AstraZeneca Aktie: Licht und Schatten bei
Astrazeneca Aktie: Starke Marktentwicklung!
Der britische Pharmariese AstraZeneca setzt nicht nur auf Medikamente, sondern zunehmend auf künstliche Intelligenz.…
Der Beitrag Astrazeneca Aktie: Starke Marktentwicklung! erschien zuerst auf kapi
3 Reasons Salesforce Is a Bargain Right Now
Shares of Salesforce Inc. (NYSE: CRM) closed just above $245 on Wednesday, as they continued to rebound off the support line around the $230 mark. This was the level where the bears ran out of
Astrazeneca Stock: Breakthrough Drug Study Boosts Shares
The British pharmaceutical giant saw its shares surge on Monday, reaching the highest level since mid-June following positive Phase III trial results for its experimental drug Baxdrostat. The
How Does D-Wave Stack Up Against Quantum Competitors?
D-Wave Quantum Inc. (NYSE: QBTS) has emerged as one of the most talked-about stocks in the quantum computing industry, a space investors are watching
iTeos verkündet Topline-Zwischenergebnisse der GALAXIES Lung-201-Studie für die First-Line-Behandlung mit Belrestotug und Dostarlimab von Krebspatienten, die von einem nicht-kleinzelligen Lungenkarzinom mit hoher PD-L1-Expression betroffen sind
– GALAXIES Lung-201 erfüllte nicht die festgelegten Kriterien für klinisch bedeutsame Verbesserungen beim progressionsfreien Überleben
– Ausgehend von der Gesamtheit der Daten haben sich iTeos und
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians
Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
Insiders bought large caps like Texas Pacific Land (NYSE: TPL), TKO Group (NYSE: TKO), and Keurig Dr Pepper (NASDAQ: KDP) in Q1, highlighting opportunities in their stocks. The question for Q2 is
AstraZeneca Stock: Strategic Expansion in Chinese Market Intensifies
AstraZeneca is bolstering its presence in the Chinese healthcare sector through a strategic acquisition worth $160 million, purchasing FibroGen's Chinese subsidiary. The deal, structured with an
Hims & Hers: From Viral Ad to Volatile Stock
Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 weeks. Shares are down 34% over that period as of the Feb. 13 close. The
Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Just when you may have finally gotten your head around the opportunity in artificial intelligence (AI), a new investment opportunity has popped up. Quantum computing is the latest “new thing”
Why AstraZeneca Stock Bumped Higher Today
AstraZeneca (NASDAQ: AZN) stock finished the trading week in style, rising by nearly 3% in value on Friday. That was due to news from the company that it's expanding its manufacturing footprint in
Where Will IonQ Be in 10 Years?
Ten years go by quickly. Duke University professors Chris Monroe and Jungang Kim founded IonQ (NYSE: IONQ) in 2015. Their goal was to develop a commercially viable quantum computer. They succeeded.
Why AstraZeneca Stock Was a Winner Today
Good news from the laboratory put some zip into AstraZeneca (NASDAQ: AZN) shares on Monday. The veteran pharmaceutical company's shares enjoyed a nearly 3% lift across the trading session as a
Why AstraZeneca Stock Topped the Market on Thursday
Veteran pharmaceutical company AstraZeneca (NASDAQ: AZN) delivered for investors on the second-to-last trading day of the week. Its shares rose by more than 3% across that trading session, thanks
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Investing in pharmaceutical stocks can carry risks. It's not always clear which drugs will be successful and turn into blockbusters for their respective businesses. As a result, it can take years
3 Magnificent Stocks Under $100 to Buy Right Now
Share price has nothing to do with whether a stock is fairly valued. However, it is nonetheless an important consideration for investors on tight budgets.
With that in mind, three Fool.com
Why AstraZeneca Stock Was Topping the Market on Tuesday
AstraZeneca (NASDAQ: AZN) reported an estimates-busting quarter Tuesday morning, and a satisfied market rewarded the company for it. At market close the sturdy pharmaceutical stock had risen by
New Horizon Aircraft Stock Soars 196%, Insider Sells 50,000 Shares
On July 10, 2025, Stewart Murray Lee (Head of People & Strategy) executed an open market sale of 50,000 shares of New Horizon Aircraft Ltd.(NASDAQ:HOVR), with the transaction disclosed in a Form 4
First Horizon Posts Q2 EPS Beat
First Horizon (NYSE:FHN), a regional banking group focused on retail and commercial lending in the Southeast, released its second quarter 2025 earnings on July 16, 2025. The most important news was
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca (NASDAQ: AZN) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that
Why AstraZeneca Stock Topped the Market on Tuesday
Trading in AstraZeneca's (NASDAQ: AZN) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly
3 No-Brainer Stocks to Buy for Under $100 Right Now
What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender. The reality is that it doesn't take much up-front cash.
Three